1
|
Monnot GC, Wegrecki M, Cheng TY, Chen YL, Sallee BN, Chakravarthy R, Karantza IM, Tin SY, Khaleel AE, Monga I, Uwakwe LN, Tillman A, Cheng B, Youssef S, Ng SW, Shahine A, Garcia-Vilas JA, Uhlemann AC, Bordone LA, Han A, Rohde CH, Ogg G, Moody DB, Rossjohn J, de Jong A. Staphylococcal phosphatidylglycerol antigens activate human T cells via CD1a. Nat Immunol 2023; 24:110-122. [PMID: 36550321 PMCID: PMC10389259 DOI: 10.1038/s41590-022-01375-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2021] [Accepted: 10/31/2022] [Indexed: 12/24/2022]
Abstract
Expressed on epidermal Langerhans cells, CD1a presents a range of self-lipid antigens found within the skin; however, the extent to which CD1a presents microbial ligands from bacteria colonizing the skin is unclear. Here we identified CD1a-dependent T cell responses to phosphatidylglycerol (PG), a ubiquitous bacterial membrane phospholipid, as well as to lysylPG, a modified PG, present in several Gram-positive bacteria and highly abundant in Staphylococcus aureus. The crystal structure of the CD1a-PG complex showed that the acyl chains were buried within the A'- and F'-pockets of CD1a, while the phosphoglycerol headgroup remained solvent exposed in the F'-portal and was available for T cell receptor contact. Using lysylPG and PG-loaded CD1a tetramers, we identified T cells in peripheral blood and in skin that respond to these lipids in a dose-dependent manner. Tetramer+CD4+ T cell lines secreted type 2 helper T cell cytokines in response to phosphatidylglycerols as well as to co-cultures of CD1a+ dendritic cells and Staphylococcus bacteria. The expansion in patients with atopic dermatitis of CD4+ CD1a-(lysyl)PG tetramer+ T cells suggests a response to lipids made by bacteria associated with atopic dermatitis and provides a link supporting involvement of PG-based lipid-activated T cells in atopic dermatitis pathogenesis.
Collapse
Affiliation(s)
- Gwennaëlle C Monnot
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA
| | - Marcin Wegrecki
- Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
| | - Tan-Yun Cheng
- Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Yi-Ling Chen
- Medical Research Council Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - Brigitte N Sallee
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA
| | - Reka Chakravarthy
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA
| | - Ioanna Maria Karantza
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA
| | - Shin Yi Tin
- Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
| | - Alexandra E Khaleel
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA
| | - Isha Monga
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA
| | - Laura N Uwakwe
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA
| | - Alice Tillman
- Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
- Microbiome and Pathogen Genomics Core, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Bin Cheng
- Department of Biostatistics, Columbia University Irving Medical Center, New York, NY, USA
| | - Soundos Youssef
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA
| | - Soo Weei Ng
- Medical Research Council Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - Adam Shahine
- Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
| | - Javier A Garcia-Vilas
- Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Anne-Catrin Uhlemann
- Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
- Microbiome and Pathogen Genomics Core, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Lindsey A Bordone
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA
| | - Arnold Han
- Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Christine H Rohde
- Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA
| | - Graham Ogg
- Medical Research Council Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - D Branch Moody
- Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Jamie Rossjohn
- Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
- Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK
| | - Annemieke de Jong
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA.
| |
Collapse
|
2
|
Stonesifer CJ, Khaleel AE, Jean-Louis G, Kwinta BD, Amengual JE, Geskin LJ. Organ-specific toxicity of romidepsin in patients with preexisting cardiovascular disease: a retrospective analysis. Leuk Lymphoma 2022; 63:1989-1992. [DOI: 10.1080/10428194.2022.2047671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Connor J. Stonesifer
- Columbia University Vagelos College of Physicians and Surgeons, New York City, USA
| | - Alexandra E. Khaleel
- Columbia University Vagelos College of Physicians and Surgeons, New York City, USA
| | - Gaston Jean-Louis
- Department of Medicine, Columbia University Irving Medical Center, New York City, USA
| | - Bradley D. Kwinta
- Columbia University Vagelos College of Physicians and Surgeons, New York City, USA
| | - Jennifer E. Amengual
- Department of Medicine, Columbia University Irving Medical Center, New York City, USA
| | - Larisa J. Geskin
- Department of Dermatology, Columbia University Irving Medical Center, New York City, USA
| |
Collapse
|
3
|
Gaydosik AM, Stonesifer CJ, Khaleel AE, Geskin LJ, Fuschiotti P. Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas. Clin Cancer Res 2022; 28:2610-2622. [PMID: 35421230 PMCID: PMC9197926 DOI: 10.1158/1078-0432.ccr-21-4437] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Revised: 02/24/2022] [Accepted: 04/11/2022] [Indexed: 12/15/2022]
Abstract
PURPOSE Clonal malignant T lymphocytes constitute only a fraction of T cells in mycosis fungoides skin tumors and in the leukemic blood of Sézary syndrome, the classic types of cutaneous T-cell lymphomas. However, lack of markers specific for malignant lymphocytes prevents distinguishing them from benign T cells, thus delaying diagnosis and the development of targeted treatments. Here we applied single-cell methods to assess the transcriptional profiles of both malignant T-cell clones and reactive T lymphocytes directly in mycosis fungoides/Sézary syndrome patient samples. EXPERIMENTAL DESIGN Single-cell RNA sequencing was used to profile the T-cell immune repertoire simultaneously with gene expression in CD3+ lymphocytes from mycosis fungoides and healthy skin biopsies as well as from Sézary syndrome and control blood samples. Transcriptional data were validated in additional advanced-stage mycosis fungoides/Sézary syndrome skin and blood samples by immunofluorescence microscopy. RESULTS Several nonoverlapping clonotypes are expanded in the skin and blood of individual advanced-stage mycosis fungoides/Sézary syndrome patient samples, including a dominant malignant clone as well as additional minor malignant and reactive clones. While we detected upregulation of patient-specific as well as mycosis fungoides- and Sézary syndrome-specific oncogenic pathways within individual malignant clones, we also detected upregulation of several common pathways that included genes associated with cancer cell metabolism, cell-cycle regulation, de novo nucleotide biosynthesis, and invasion. CONCLUSIONS Our analysis unveils new insights into mycosis fungoides/Sézary syndrome pathogenesis by providing an unprecedented report of the transcriptional profile of malignant T-cell clones in the skin and blood of individual patients and offers novel prospective targets for personalized therapy.
Collapse
Affiliation(s)
- Alyxzandria M. Gaydosik
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh PA 15261, USA
| | | | | | | | - Patrizia Fuschiotti
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh PA 15261, USA,Correspondence to: Patrizia Fuschiotti, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, S709 BST, 200 Lothrop Street, Pittsburgh PA 15261, USA. Tel.: +1-412-648-9385;
| |
Collapse
|
4
|
Stonesifer CJ, Khaleel AE, Garcia-Saleem TJ, Husain S, Geskin LJ. Isolated Cutaneous Pseudallescheria Boydii Abscess in an Immunocompetent Man. JAAD Case Rep 2022; 21:160-164. [PMID: 35242972 PMCID: PMC8873215 DOI: 10.1016/j.jdcr.2021.12.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Affiliation(s)
- Connor J. Stonesifer
- Columbia University Vagelos College of Physicians and Surgeons, New York, New York
| | - Alexandra E. Khaleel
- Columbia University Vagelos College of Physicians and Surgeons, New York, New York
| | | | - Sameera Husain
- Department of Dermatology, Columbia University Irving Medical Center, New York, New York
| | - Larisa J. Geskin
- Department of Dermatology, Columbia University Irving Medical Center, New York, New York
- Correspondence to: Larisa J. Geskin, MD, Department of Dermatology, Herbert Irving Pavilion, 12th Floor, 161 Fort Washington Avenue, New York, NY 10032.
| |
Collapse
|
5
|
Stonesifer CJ, Djavid AR, Grimes JM, Khaleel AE, Soliman YS, Maisel-Campbell A, Garcia-Saleem TJ, Geskin LJ, Carvajal RD. Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence. Front Oncol 2021; 11:734354. [PMID: 34988009 PMCID: PMC8720968 DOI: 10.3389/fonc.2021.734354] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Accepted: 10/15/2021] [Indexed: 12/17/2022] Open
Abstract
Immuno-oncology is a rapidly evolving field with growing relevance in the treatment of numerous malignancies. The prior study of immunotherapy in dermatologic oncology has largely focused on cutaneous melanoma. However, recent focus has shifted to the use of immunotherapy to treat non-melanoma skin cancers (NMSCs), such as basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and Merkel cell carcinoma (MCC). NMSCs represent the most ubiquitous cancers globally and, while they have a lower propensity to develop into advanced disease than cutaneous melanoma, their absolute mortality burden has recently surpassed that of melanoma. Patients with advanced NMSC are now benefiting from the successes of immunotherapy, including checkpoint inhibition with anti-CTLA-4 and anti-PD-1 monoclonal antibodies. In this review, we discuss the existing clinical evidence for immunotherapy in the treatment of NMSCs, with an emphasis on checkpoint inhibitor therapies. We highlight key studies in the field and provide up-to-date clinical evidence regarding ongoing clinical trials, as well as future study directions. Our review demonstrates that checkpoint inhibitors are positioned to provide unparalleled results in the previously challenging landscape of advanced NMSC treatment.
Collapse
Affiliation(s)
- Connor J. Stonesifer
- Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, United States
| | - A. Reza Djavid
- Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, United States
| | - Joseph M. Grimes
- Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, United States
| | - Alexandra E. Khaleel
- Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, United States
| | - Yssra S. Soliman
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, United States
| | - Amanda Maisel-Campbell
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, United States
| | - Tiffany J. Garcia-Saleem
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, United States
| | - Larisa J. Geskin
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, United States
| | - Richard D. Carvajal
- Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States
| |
Collapse
|
6
|
Garcia-Saleem TJ, Stonesifer CJ, Khaleel AE, Geskin LJ. Management of Mycosis Fungoides with Topical Chlormethine/Mechlorethamine Gel: A Columbia University Cutaneous Lymphoma Center Experience. Acta Derm Venereol 2021; 101:adv00544. [PMID: 34436621 PMCID: PMC9425598 DOI: 10.2340/00015555-3911] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Mycosis fungoides is a type of cutaneous T-cell lymphoma, which accounts for the majority of cases of cutaneous T-cell lymphoma. Mycosis fungoides can be classified as early-stage (IA–IIA) or late-stage (IIB or greater) disease. In early-stage mycosis fungoides, skin-directed therapies are commonly used to manage the disease. Chlormethine, or mechlorethamine, is a topical chemotherapeutic, which has been in use for over 60 years. In 2013, the US Food and Drug Administration approved chlormethine/mechlorethamine gel (Valchlor®) for treatment of stage IA and IB mycosis fungoides. Chlormethine/mechlorethamine gel is an effective therapy; however, its use may be limited by the development of adverse cutaneous reactions. Off-label dosing modifications, as well as co-administration of topical steroids and an aggressive moisturization regimen, can be used to reduce these side-effects. We report here 4 cases of mycosis fungoides treated with chlormethine/mechlorethamine gel at the Comprehensive Skin Cancer Center at Columbia University Irving Medical Center, which provide insights into the use of this therapy in clinical practice.
Collapse
|